Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics Inc. has announced the appointment of biotech industry leader Abigail Jenkins to its Board of Directors, bringing over two decades of experience in advancing therapies from research to commercialization. Her expertise is expected to be particularly valuable as XORTX transitions from a Phase 3 clinical company towards commercializing its drug candidates. Jenkins holds impressive credentials, including a Master of Science from Johns Hopkins University, and has been recognized as a transformative leader in the industry.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
